PAR-25-175-Full-Announcement.html

This document is a Notice of Funding Opportunity (NOFO) for the "Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)" federal grant opportunity, solicitation number PAR-25-175.

The National Cancer Institute (NCI), part of the Department of Health and Human Services National Institutes of Health, is seeking research project (R01) grant applications that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy to determine the optimal use of those modalities in characterizing therapy response and/or emergence of resistance. Eligible applicant types include public and private organizations, small businesses, and non-profit entities. The funding opportunity is assigned to the Cancer Detection and Diagnosis Research (CFDA 93.394) and Cancer Treatment Research (CFDA 93.395) federal grant programs. No award amount or timeline is specified in the document provided.